KLK4 and hepatocellular carcinoma: Application of KBP, which specifically binds to tissue kallikrein and inhibits kallikrein activity, was reported to suppress growth of HCC in mice possibly via its anti-angiogenic activity [33], suggesting the possible involvement of KLKs in the progression of HCC.